You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大和:藥明生物(02269.HK)配股助捕捉新冠疫苗產能擴張機遇 重申「買入」看135元
阿思達克 02-03 12:34
藥明生物(02269.HK)公布計劃配售1.18億股股份,佔擴大後股本2.8%,每股配售價112元,較昨日(2日)收市價折讓6.98%,預計所得款項淨額131.21億元。大和發表研究報告指,這是公司歷史上第四次新股配售。大和料配股可強化公司財政實力,更好地捕捉新冠mRNA疫苗潛在外包需求。

目前在歐洲及美國,至今有兩款mRNA疫苗(Moderna及輝瑞/BioNTech)獲批。不過,報告稱,製造產能缺口成為疫苗分發的重大阻礙。因此,歐盟上周五(1月29日)就區內生產疫苗推臨時出口限制。大和認為,現時疫苗供應問題為生物製劑CDMO企業額外產能帶來緊急而龐大需求。

大和進一步稱,藥明生物去年12月從拜耳收購德國原液/製劑(DS/DP)設施,隨著配股集資取得新資金,公司已準備好下半年贏得潛在mRNA疫苗生產合約。該行重申藥明生物「買入」評級及目標價135元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account